5 February 2019

Jack Schalken and Vicky Luna Velez and colleagues, theme Urological cancers, published in Oncogene about suppression of prostate tumor cell survival by antisense oligonucleotide-mediated inhibition of AR-V7 mRNA synthesis.

Publication in Oncogene: link.
Jack Schalken
Vicky Luna Velez

One of the mechanisms by which advanced prostate cancer develops resistance to androgen deprivation therapy is the elevated expression of C-terminally truncated androgen receptor (AR) variants. These variants, such as AR-V7, originate from aberrant splicing of the AR pre-mRNA and the inclusion of a cryptic exon containing a premature stop codon in the mRNA. The resulting loss of the ligand-binding domain allows AR-V7 to act as a constitutively active transcription factor. They designed two antisense oligonucleotides (AONs) directed against cryptic splicing signals within the AR pre-mRNA. These two AONs, AON-ISE and AON-ESE, demonstrated high efficiency in silencing AR-V7 splicing without affecting full-length AR expression. The subsequent downregulation of AR-V7-target gene UBE2C was accompanied by inhibition of androgen-independent cell proliferation and induction of apoptosis in castration-resistant prostate cancer (CRPC)-derived cell line models 22Rv1, DuCaP, and VCaP.
 
Their results show that splicing-directed AONs can efficiently prevent expression of AR-V7, providing an attractive new therapeutic option for the treatment of CRPC (castration-resistant prostate cancer).
 

Related news items


RIMLS award ceremony proudly presenting the winners

16 January 2020

Several RIMLS researchers received an award and bonus during the New Year's drinks. See all photo's and the ENABLE aftermovie.

read more

Stofwisselkracht grant for Daan Panneman and Richard Rodenburg

16 January 2020

Daan Panneman & Richard Rodenburg have been awarded a Stofwisselkracht grant for their proposal “CRISPR/Cas9 knock-in complementation in fibroblasts of mitochondrial disease patients”. Together with Omar Tutakhel & Jan Smeitink they will investigate the possibility of using CRISPR/Cas9 knock-in.

read more

Radboud Talks 2020 scientific pitch competition

14 January 2020

The next edition of Radboud Talks will take place in the spring. During this academic pitch competition, young researchers will be given the opportunity to share their stories with a large audience. In a three-minute presentation, you will talk about your research in a fun and accessible manner.

read more

Rubicon Grant for Sami Mohammed

14 January 2020

Former RIMLS researcher Sami Mohammed, theme Renal disorders, received a Rubicon Grant from the Dutch Organisation for Scientific Research (NWO). The Rubicon program gives young, highly promising researchers the opportunity to gain international research experience.

read more

Review Sanne Frambach accepted by Pharmacological Reviews

13 January 2020

In this review entitled 'Brothers in arms: ABCA1 and ABCG1-mediated cholesterol efflux as promising targets in cardiovascular disease treatment', RIMLS researcher Sanne Frambach, describe the possibilities for stimulating cellular efflux.

read more

Prostate cancer can now be diagnosed better using artificial intelligence

9 January 2020

RIHS researchers Wouter Bulten and Geert Litjens have developed a ‘deep learning’ system that is better than most pathologists at determining the aggressiveness of prostate cancer. The Artificial Intelligence system taught itself to identify prostate cancer based on data from over 1200 patients.

read more